NCCN Guidelines® Insights Myeloproliferative Neoplasms, Version 2.2018 Featured Updates to the NCCN Guidelines
NCCN Guidelines® Insights Myeloproliferative Neoplasms, Version 2.2018 Featured Updates to the NCCN Guidelines
复制标题
DOI：
10.6004/jnccn.2017.0157
复制
发表时间：
2017-10-01
影响因子：
13.4
通讯作者：
Sundar, Hema
中科院分区：
文献类型：
--
作者：
Mesa, Ruben A.;Jamieson, Catriona;Sundar, Hema
骨髓增生性肿瘤(MPN)是一组异质性的造血系统疾病，包括骨髓纤维化(MF)、真性红细胞增多症(PV)和原发性血小板增多症(ET)。PV和ET的特点是显著的血栓出血性并发症，以及转化为MF和急性髓系白血病的高风险。自从发现与其发病机制有关的突变后，PV和ET的诊断和治疗就得到了发展。这些NCCN指南洞察讨论了NCCN指南中概述的关于PV和ET管理的风险分层、治疗和特殊考虑的建议。
Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.